Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

被引:713
作者
Heerspink, H. J. Lambers [1 ]
de Zeeuw, D. [1 ]
Wie, L. [3 ]
Leslie, B. [2 ]
List, J. [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands
[2] Bristol Myers Squibb Co, Global Clin Res, Princeton, NJ USA
[3] Bristol Meyer Squibb, Global Biometr Sci, Hopewell, NJ USA
关键词
blood pressure; dapagliflozin; HbA1c; renal function; type; 2; diabetes; INADEQUATE GLYCEMIC CONTROL; GLOMERULAR HYPERFILTRATION; SGLT2; INHIBITOR; METFORMIN; MELLITUS; THERAPY; EXCRETION; WEIGHT; VOLUME; GFR;
D O I
10.1111/dom.12127
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have diuretic-like physiologic effects, we compared dapagliflozin and hydrochlorothiazide (HCTZ) effects on 24-h blood pressure (BP), body weight, plasma volume and glomerular filtration rate (GFR). Methods: In this randomized, placebo-controlled, double-blind trial, 75 subjects with type 2 diabetes were assigned placebo, dapagliflozin 10 mg/day, or HCTZ 25mg/day. Changes from baseline BP, body weight, plasma volume and GFR were assessed after 12 weeks of treatment. Results: Subjects' mean age was 56 years, type 2 diabetes mellitus (T2DM) duration 6.3 years, and haemoglobin A1c (HbA1c) 7.5%. Treatment with placebo, dapagliflozin or HCTZ resulted in changes from baseline in 24-h ambulatory mean systolic blood pressure (SBP) of -0.9 (95% CI -4.2, +2.4), -3.3 (95% CI -6.8, +0.2), and -6.6 (95% CI -9.9, -3.2) mmHg, respectively at week 12, adjusted for baseline SBP. Body weight decreased with dapagliflozin and HCTZ. In a sub-study plasma volume appeared to decrease with dapagliflozin but did not change with placebo or HCTZ treatment. Dapagliflozin induced a greater reduction in GFR (-10.8%; 95% CI -14.6, -6.7) relative to placebo (-2.9%; 95% CI -6.9, +1.2) or HCTZ (-3.4%; 95% CI -7.3, +0.6). Conclusions: Dapagliflozin-induced SGLT2 inhibition for 12 weeks is associated with reductions in 24-h BP, body weight, GFR and possibly plasma volume. Cumulatively, these effects suggest that dapagliflozin may have a diuretic-like capacity to lower BP in addition to beneficial effects on glycaemic control.
引用
收藏
页码:853 / 862
页数:10
相关论文
共 22 条
[1]  
[Anonymous], J AM SOC NEPHROLOGY
[2]   Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].
Bailey, Clifford J. ;
Gross, Jorge L. ;
Pieters, Anne ;
Bastien, Arnaud ;
List, James F. .
LANCET, 2010, 375 (9733) :2223-2233
[3]   Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications [J].
Bakris, George L. ;
Fonseca, Vivian A. ;
Sharma, Kumar ;
Wright, Ernest M. .
KIDNEY INTERNATIONAL, 2009, 75 (12) :1272-1277
[4]   Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].
Bolinder, Jan ;
Ljunggren, Osten ;
Kullberg, Joel ;
Johansson, Lars ;
Wilding, John ;
Langkilde, Anna Maria ;
Sugg, Jennifer ;
Parikh, Shamik .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031
[6]   Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients [J].
Christensen, PK ;
Hansen, HP ;
Parving, HH .
KIDNEY INTERNATIONAL, 1997, 52 (05) :1369-1374
[7]   HEMODYNAMIC AND HYPOTENSIVE EFFECTS OF LONG-TERM THERAPY WITH CHLOROTHIAZIDE [J].
CONWAY, J ;
LAUWERS, P .
CIRCULATION, 1960, 21 (01) :21-27
[8]   Effect on glycernic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM [J].
Feinglos, M ;
Dailey, G ;
Cefalu, W ;
Osei, K ;
Tayek, J ;
Canovatchel, W ;
Chaiken, R ;
Kourides, I .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 68 (02) :167-175
[9]  
Gaspari F, 1998, J AM SOC NEPHROL, V9, P310
[10]   EFFECT OF THIAZIDE DIURETICS ON PLASMA VOLUME, BODY ELECTROLYTES, AND EXCRETION OF ALDOSTERONE IN HYPERTENSION [J].
GIFFORD, RW ;
MATTOX, VR ;
ORVIS, AL ;
ROSEVEAR, JW ;
SONES, DA .
CIRCULATION, 1961, 24 (05) :1197-&